Biopharma companies have spent years discussing supply chain resilience, but inventory buffers and backup suppliers do little against today’s deeper challenge. Demanding modalities, fragmented networks, evolving regulation and geopolitical uncertainty keep adding complexity and risk. In this white paper, Jagruti Patel, Senior Director, Commercial Development, Integrated Biologics at Lonza, explains how strategic outsourcing can help biopharma organizations manage that complexity.
“We see resilience as the ability to absorb rising complexity without passing that complexity back to customers or patients.”
Jagruti Patel
Discover in this white paper:
- Why traditional resilience measures such as stockpiling and supplier diversification fall short against today’s root challenges
- How rising complexity in modalities, networks, regulation and geopolitics increases exposure to disruption
- The four capabilities that make a resilient manufacturing partner: adaptable multi-scale, multi-region networks; integrated systems; deep technical expertise; and digital decision-making
- How the role of CDMOs is shifting from capacity provider to strategic partner
- What defines a successful partnership today: operational agility, technical excellence and alignment with customer goals
